Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel ...

Under the collaboration agreement, the parties will combine Harbour BioMed's industry-leading technology platform, proprietary dataset and extensive expertise in antibody development with Insilico's ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

At the recent annual congress of the European Association for Haemophilia and Allied Disorders, researchers from Novalgen Ltd. presented the discovery and preclinical characterization NVG-444, a ...

Researchers have found a new class of antibodies to treat malaria ... breakthrough that could help development of a new next-generation antimalarial interventions," Cristina Donini told DW.

Biomissile Pharmaceuticals Co. Ltd. is developing multispecific antibodies that overcome resistance associated with antibody-drug conjugates via its next-generation natural killer (NK) cell engagers.

AbbVie has entered a partnership and option-to-license agreement with Xilio Therapeutics to develop new tumour-activated, ...